SSY GROUP (02005): 95 varieties of products included in the National Essential Medicines List (2026 edition)

SSY GROUP (02005) announced that a total of 95 varieties (141 specifications) of products from the group have been included in the Chinese "National Essential Medicines List (2026 Edition)", including 32 newly added varieties (37 specifications), which are Glucose and Sodium Chloride Injection, Levofloxacin Lactate Sodium Chloride Injection, Levofloxacin Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Glimepiride Tablets, Qingre Jiedu Oral Liquid, Potassium Chloride Injection, Mecobalamin Injection, Amisulpride Hydrobromide Injection, Bromhexine Hydrochloride Injection, Medium/Long Chain Fat Emulsion Injection, Injection Lincomycin, Acetylsalicylic Acid Tablets, Azithromycin Dry Powder for Suspension, Ipratropium Bromide Inhalation Solution, Lurasidone Hydrochloride Tablets, Urapidil Hydrochloride Injection, Colchicine Sodium Phosphate Injection, Oseltamivir Phosphate Dry Powder for Suspension, Aminophylline Injection, Magnesium Sulfate Injection, Cefuroxime Axetil Dry Powder for Suspension, Ondansetron Hydrochloride Injection, Entacapone Tablets, Isosorbide Dinitrate Injection, Betahistine Mesylate Tablets, Epinephrine Bitartrate Injection, Amlodipine Besylate Tablets, Levofloxacin Eye Drops, Propafenone Hydrochloride Injection, and Metoclopramide Hydrochloride Injection. This list will be implemented starting on September 1, 2026, and is expected to have a positive impact on the group's growth and business development.